Search for: metastatic renal

• 320 Results (Page 1 of 16)
• • Relevance 

    • Relevance
    • Published
    • Price
    Sort by Relevance Published Price

Metastatic Renal Cell Carcinoma (mRCC) - Pipeline Insight, 2020

•  Clinical Trials
• February 2020
• 106 pages

From

€1320EUR$1,500USD£1,140GBP

Metastatic Renal Cell Carcinoma (Oncology) - Drugs in Development, 2021

•  Report
• April 2021
• 170 pages

From

€1760EUR$2,000USD£1,520GBP

Metastatic Renal Cell Carcinoma (mRCC) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019

•  Drug Pipelines
• January 2019
• 60 pages

From

€1760EUR$2,000USD£1,520GBP

Metastatic Renal Cell Carcinoma - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

•  Drug Pipelines
• January 2017
• 100 pages

From

€1760EUR$2,000USD£1,520GBP

2019 Metastatic Renal Cell Carcinoma Ongoing Clinical Trials Study- Companies, Countries, Drugs, Phases, Enrollment, Current Status and Markets

•  Clinical Trials
• February 2019
• 200 pages

From

€1548EUR$1,759USD£1,337GBP

€1935EUR$2,199USD£1,671GBP

Metastatic Renal Cell Cancer - Pipeline Insights, 2017

•  Clinical Trials
• January 2017
• 60 pages

From

€1100EUR$1,250USD£950GBP

Metastatic Renal Cell Carcinoma - Pipeline Insights, 2017

•  Clinical Trials
• January 2017
• 60 pages

From

€1100EUR$1,250USD£950GBP

Renal Cell Cancer (RCC) Disease Forecast and Market Analysis to 2038

•  Report
• April 2021
• 74 pages

€19360EUR$22,000USD£16,720GBP

Advanced Renal Cell Carcinoma Epidemiology Forecast - 2028

•  Report
• December 2019
• 100 pages

From

€2860EUR$3,250USD£2,470GBP

Bevacizumab Biosimilar Market Opportunity, Sales, Price & Clinical Trials Insight 2025

•  Report
• December 2020
• 120 Pages

From

€1760EUR$2,000USD£1,520GBP

Advanced Renal Cell Carcinoma Market Insights, Epidemiology and Market Forecast - 2028

•  Report
• December 2019
• 200 pages

From

€5500EUR$6,250USD£4,750GBP

Advanced and Metastatic Renal Cell Carcinoma An Issue of Urologic Clinics. The Clinics: Surgery Volume 47-3

•  Book
• July 2020

€92EUR$111USD£82GBP

Interleukin-2, a Tale of Two Halves: To Suppress or Augment Suppression, That is the Question

•  Report
• May 2019
• 17 Pages

From

€2200EUR$2,500USD£1,900GBP

Metastatic Renal Cell Carcinoma Ongoing Global Clinical Trials Analysis and Outlook

•  Report
• June 2018
• 166 pages

From

€493EUR$560USD£426GBP

€616EUR$700USD£532GBP

BRIC Embolization Particle Procedures Outlook to 2025 - Embolization Particle Procedures to treat Arteriovenous Malformations, Embolization Particle Procedures to treat Benign prostatic hyperplasia and Others

•  Report
• November 2020
• 132 pages

From

€3516EUR$3,995USD£3,036GBP

North America Embolization Particle Procedures Outlook to 2025 - Embolization Particle Procedures to treat Arteriovenous Malformations, Embolization Particle Procedures to treat Benign prostatic hyperplasia and Others

•  Report
• November 2020
• 100 pages

From

€3516EUR$3,995USD£3,036GBP

EU5 Embolization Particle Procedures Outlook to 2025 - Embolization Particle Procedures to treat Arteriovenous Malformations, Embolization Particle Procedures to treat Benign prostatic hyperplasia and Others

•  Report
• November 2020
• 160 pages

From

€3516EUR$3,995USD£3,036GBP

Asia-Pacific Embolization Particle Procedures Outlook to 2025 - Embolization Particle Procedures to treat Arteriovenous Malformations, Embolization Particle Procedures to treat Benign prostatic hyperplasia and Others

•  Report
• November 2020
• 160 pages

From

€3516EUR$3,995USD£3,036GBP

Canada Embolization Particle Procedures Outlook to 2025 - Embolization Particle Procedures to treat Arteriovenous Malformations, Embolization Particle Procedures to treat Benign prostatic hyperplasia and Others

•  Report
• August 2020
• 43 pages

From

€2636EUR$2,995USD£2,276GBP

Urothelial Carcinoma - Market Insights, Epidemiology and Market Forecast - 2028

•  Report
• September 2019
• 254 pages

From

€5500EUR$6,250USD£4,750GBP

• 320 Results (Page 1 of 16)
• • 1
  • 2
  • 3
  • 